Vectura Group (VEC) Earns Buy Rating from Numis Securities

Numis Securities reissued their buy rating on shares of Vectura Group (LON:VEC) in a research report report published on Thursday, March 22nd. The firm currently has a GBX 160 ($2.29) target price on the stock.

VEC has been the subject of a number of other reports. Royal Bank of Canada raised Vectura Group to a sector performer rating and set a GBX 119 ($1.70) target price for the company in a report on Thursday, December 14th. Shore Capital reissued a hold rating on shares of Vectura Group in a report on Wednesday, March 21st. JPMorgan Chase reaffirmed an overweight rating on shares of Vectura Group in a report on Monday, January 15th. Citigroup reaffirmed a buy rating and set a GBX 155 ($2.22) price target on shares of Vectura Group in a report on Tuesday, March 20th. Finally, Peel Hunt dropped their price target on Vectura Group from GBX 160 ($2.29) to GBX 120 ($1.72) and set a hold rating for the company in a report on Wednesday, February 14th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of GBX 139.38 ($2.00).

How to Become a New Pot Stock Millionaire

LON:VEC traded down GBX 7.50 ($0.11) during mid-day trading on Thursday, hitting GBX 97 ($1.39). 11,244,078 shares of the company’s stock traded hands, compared to its average volume of 4,610,000. Vectura Group has a 12 month low of GBX 70 ($1.00) and a 12 month high of GBX 166.97 ($2.39).

ILLEGAL ACTIVITY NOTICE: “Vectura Group (VEC) Earns Buy Rating from Numis Securities” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at

About Vectura Group

Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company's marketed products include Ultibro Breezhaler and Seebri Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; and Adept for the treatment of surgical adhesions.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with's FREE daily email newsletter.

Leave a Reply